Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Algeta

Bayer symbol

Bayer moves heart failure candidate finerenone into phase III

Follows positive phase IIb data presented at the European Society of Cardiology(ESC) meeting

- PMLiVE

NICE backs Bayer’s Eylea in diabetic eye condition

TheInstitute also recommends Allergan's Ozurdex in final guidance

- PMLiVE

Bayer sells diabetes division to Panasonic Healthcare

€1.02bn sale includes Contour electronic meters and other medical devices

- PMLiVE

Bayer renews contract with Ashfield Meetings & Events

Partnership have been working together since 2012

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

- PMLiVE

Eylea growth closes the gap with Lucentis

Bayer/Regeneron’s drug eye disease drug set for blockbuster status

- PMLiVE

Kythera bags FDA approval for double chin therapy

Comes as cosmetics industry sees major growth

- PMLiVE

Quality in Care anticoagulation programme open for entry

PMGroup's QiC programme aims to recognise best practice in care in the UK

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

- PMLiVE

Bayer’s Eylea cleared for wider use in Europe

Macular oedema treatment reached €759m in sales last year

- PMLiVE

UK doctors call on NHS to use Avastin for wet AMD

Controversial practice of using the drug off-label could save the health service £102m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links